Apimeds Pharmaceuticals US, Inc.
APUS· NYSE
Released Nov 16, 2026, after the close
10-Q filed Nov 16, 2026, 47 days after period end · 0001213900-26-120578
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q3 2026 | Q3 2025 | Q3 2024 |
|---|---|---|---|
| Revenue | $2.90M | — | — |
| Net Income | $33.65M | -$1.78M | -$332.52K |
| EPS Diluted | $7.68 | -$1.42 | -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Apimeds Pharmaceuticals US, Inc. · CIK 1894525 · Engraved from SEC EDGAR